The CA 72.4 tumor marker is composed of two monoclonal antibodies, B 72.3 and cc49, which detect the glycoprotein TAG 72 present in tumor cells. The levels of CA 72.4 can be influenced by the excretion route of the TAG 72 antigen.
A study aimed to evaluate the behavior of CA 72.4 in healthy individuals and to assess the impact of chronic renal failure (CRF) on the marker's levels. The study involved 181 participants (148 healthy volunteers and 33 patients with CRF), with 214 determinations of CA 72.4 and 66 plasma creatinine tests.
In healthy subjects, the cutoff value for CA 72.4 was established at 3 U/mL, showing a sensitivity of 53% and a specificity of 85.8%. Among CRF patients, no significant differences were observed between pre-dialysis and post-dialysis CA 72.4 levels (p = 0.197). However, plasma creatinine levels showed a significant difference (p < 0.001).
The study concluded that chronic renal failure does not affect CA 72.4 levels, making this tumor marker reliable for monitoring cancer patients, regardless of their renal function. Therefore, CA 72.4 can be effectively used for cancer management and monitoring without interference from renal failure.
Test Type:
Blood
Reporting:
Fourth Day (Max. by 11 PM)
Free Home/Office Sample Collection
Fasting:
Fasting not mandatory
Best & Honest Price
One Prick Sample Collection Policy